Keywords
Oral and maxillofacial surgery, Postoperative pain, Multimodal analgesia, Non-opioid analgesics, Opioids, Local anesthetics, Pain management

Authors
Dr. Avinash Sonune[1*]
Assistant Professor , Government Medical College Washim, Department Of Dentistry, Maharashtra University Of Health Sceinces Nashik, Washim, 444505, India. Email ID: avinashsonune01@gmail.com
ORCID ID: 0009-0008-0689-3715

Dr S Nachiappan[2]
Professor and HOD, Department of Oral and Maxillofacial Surgery, Sathyabama Dental College and Hospital, Chennai - 119, Email ID - nachibds@yahoo.com
ORCID ID - 0000-0002-6036-3001

Lasya Marupudi[3]
Pharma. D intern, Department of Pharmacy Practice, Sri Venkateshwara College of Pharmacy; Osmania University.
Email ID: lasyamarupudi@gmail.com
ORCID ID: 0009-0000-8616-6869

Dr. Pratik Bhatnagar[4]
Associate Professor, Government Dental College and Hospital, Jamnagar, Saurashtra University, Gujarat. Email ID: bhatnagarpratik99@gmail.com
ORCID ID: 0000-0003-1739-1645

Dr Rajat Mohanty[5]
Professor, Department of Oral and Maxillofacial Surgery, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Bhubaneswar, Odisha
Email ID: rajatmohanty007@gmail.com
ORCID ID: 0009-0000-9050-0129

Address for correspondence: Dr. Avinash Sonune, Assistant Professor , Government Medical College Washim, Department Of Dentistry, Maharashtra University Of Health Sceinces Nashik, Washim, 444505, India.
Email ID: avinashsonune01@gmail.com
ORCID ID: 0009-0008-0689-3715

Received:16-06-2026
Revised: 22-07-2026
Accepted: 28-07-2026
Doi:10.1922/ejprd.v34i7s.1651

Pharmacological Strategies for Surgical Pain Management in Oral and Maxillofacial Procedures: Safety and Clinical Outcomes

Abstract

Background: Surgical pain following oral and maxillofacial procedures is a common and clinically significant outcome resulting from tissue injury, inflammation, and neural sensitization, with implications for recovery, function, and patient satisfaction.

Objective: To evaluate current pharmacological strategies for managing surgical pain in oral and maxillofacial procedures, with emphasis on safety profiles and clinical outcomes.

Methods: A narrative review of contemporary literature was conducted, focusing on pharmacological interventions including non-opioid analgesics, opioids, local anesthetics, corticosteroids, and emerging agents, along with multimodal analgesic approaches and their impact on postoperative outcomes.

Results: Non-opioid analgesics, particularly NSAIDs and paracetamol, demonstrated consistent efficacy as first-line agents for postoperative dental pain. Multimodal analgesia combining agents with different mechanisms provided superior pain control and reduced opioid requirements. Opioid use was associated with significant adverse effects and is increasingly limited to selected cases. Adjunctive therapies such as corticosteroids and long-acting local anesthetics contributed to improved outcomes. Emerging agents, including selective sodium channel inhibitors, showed potential for effective opioid-sparing analgesia. Safety considerations varied across drug classes, with gastrointestinal, renal, and central nervous system effects being concerns.

Conclusion: Pharmacological pain management in oral and maxillofacial surgery has evolved toward multimodal, opioid-sparing strategies that enhance efficacy and safety. Individualized treatment planning based on patient and procedural factors is essential for optimizing clinical outcomes.

INTRODUCTION

Post-surgical pain is a predictable but clinically significant manifestation of tissue injury, inflammation, and neural stimulation, which is experienced following oral and maxillofacial surgery. Third molar extraction, dental implant, orthognathic surgery, oral cancer resection, among others are the types of surgeries that frequently lead to moderate to severe postoperative pain that, if not well managed, may impact the recovery of functionality, the healing process, and negatively impact the patient's satisfaction and quality of life. The successful management of pain is thus an important aspect of the perioperative care in oral and maxillofacial surgery that directly affect the clinical outcomes and use of healthcare [1]. The pathophysiology of postoperative pain are multifactorial in this field with nociceptive and inflammatory processes. Prostaglandins, bradykinin and cytokines are inflammatory mediators secreted in surgical trauma and sensitise the peripheral nociceptors and enhance pain transmission. Moreover, the central sensitisation of the spinal and trigeminal pathways could also increase the perception of pain, especially when it comes to situations with a large amount of tissue manipulation or nerve damage. The psychological factors such as anxiety before the operation and the previous experience with pain also moderate the perception of pain and cause interindividual difference in pain reactions [2]. These multifaceted processes necessitate a multi-modal and personalised approach to pain management which must be based on pharmacology.

The use of pharmacological methods are the staple of pain management following surgery in the maxillofacial and oral surgeries. Conventionally, the non-opioid agents of nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol have been used while opioid analgesics have been used in the treatment of more severe pains. NSAIDs have their action involved in inhibiting the enzymes cyclooxygenase and reducing the production of prostaglandins and inflammation whereas paracetamol provides central analgesia and has an acceptable safety profile [3]. By their action at mu-opioid receptors, Opioids have a very potent analgesic action but are associated with significant risks such as respiratory depression, nausea, constipation, tolerance and misuse and dependence propensities. Such restrictions have ushered in a new approach of reduction of opioid consumption and focusing on safer and non-opioid options.

The recent advancements in pharmacology have improved the number of available painkilling agents with the advent of new pain pathways taking agents. Indicatively, NAV1.8 blockers as selective sodium channels inhibitors have proved to be as promising non-opioid therapeutics in the management of acute pain, which provide effective analgesia and do not lead to severe side effects like opioids [4]. Also, synergistic effects of fixed-dose combinations of analgesics, e.g. ibuprofen with acetaminophen or caffeine, were found to increase analgesic efficacy, and may reduce required doses. Corticosteroids, longer lasting local anesthetics and adjuvant agents, including gabapentinoids, also play a part in multimodal analgesia by acting on other parts of the pain pathway.

The concept of multimodal analgesia has taken center stage as one of the important measures in the modern pain treatment. This method implies the simultaneous administration of two or more pharmacological agents with different mechanisms of action in order to achieve better analgesia and less occurrence of side effects. Multimodal regimens have proven to be able to reduce the intensity of postoperative pain, the use of opioids, and improve patient outcomes in general in the case of oral and maxillofacial surgery. Another method that has been investigated is preemptive analgesia, which is given before surgical insult so as to alleviate central sensitization and improve the effect of controlling postoperative pain [5]. The safety is a factor which has not been excluded in the administration and choice of analgesic agents. Although effective, NSAIDs might be associated with some gastrointestinal irritation, kidney impairment and the risk of bleeding particularly with vulnerable people. Opioids carry with them dependency and adverse systemic consequences that must be prescribed and monitored with care. Local anesthetic drugs can cause systemic toxicity if used in false way although they are in general harmless. Moreover, any factors by the patient such as age, comorbid diseases, drugs co-prescribed and genetic diversity impact on the metabolism and response of the medication, this promotes the necessity of patient-specific treatment planning [6].

Clinical outcomes that relate to pharmacological pain management do not just limit themselves to reduction of pain. Pain management helps to prevent medical-related complications, relieve patients and promote compliance with postoperative care rules. On the other hand, the failure to manage pain successfully has been linked to such complications as delayed recovery, the onset of chronic pains and frequent visits to the health care department. New data also points at the importance of non-pharmacological supports and psychological interventions in controlling the process of perception of pain, although pharmacological management is the major focus of the postoperative care in the short term [7].

There are still challenges in streamlining pain management in oral and maxillofacial surgery that are still present despite the significant advances. Unpredictability in clinical practice, inadequate standardization of protocols, and the issues of drug safety and effectiveness still remain to have an impact on decision making. In order to fill in these gaps and improve the results of those patients, it is necessary to carry out continuous studies in new analgesics, new forms of personalized medicine, and evidence-based guidelines [8].

The objective of this review includes a thorough examination of pharmacological treatment of surgical pain during oral and maxillofacial surgery as well as the discussion of safety profiles and clinical outcomes in particular. It attempts to inform clinical practice and support in the design of effective, and patient-centered, pain management protocols through the combination of existing evidence.

Mechanisms of Pain in the Oral and Maxillofacial Surgery

The nociceptive, inflammatory, and neuropathic mechanisms interact in a complex manner to cause postoperative pain in oral and maxillofacial surgery. The damage of tissues during surgical procedures, e.g., the removal of the third molar, implantation, or orthognathic surgery, triggers a sequence of biochemical processes, marked by the release of inflammatory mediators, e.g., prostaglandins, histamine, serotonin, and cytokine. These mediators stimulate and sensitise the peripheral nociceptors found in the oral mucosa, periosteum and the surrounding soft tissues resulting in the production of pain signals that are transduced by trigeminal nerve fibres to the central nervous system [9]. The peripheral sensitization is a key determinant of the enhancement of the postoperative pain. After surgical trauma, nociceptors are sensitive to lower activation threshold and become hypersensitive to stimuli that leads to a higher perception of pain even to minor mechanical or thermal stimuli. This effect leads to primary hyperalgesia in the place of injury. Simultaneously, the central sensitization takes place in the spinal trigeminal nucleus and upper centers of pain processing, where recurring nociceptive signals increase synaptic processing and result in chronic pain conditions [10]. Central sensitization is especially applicable in those cases when the manipulation of the central nervous system is conducted over a long period or in complex surgical operations, and it can be one of the factors leading to the acute to chronic pain.

Most of the oral surgical procedures are accompanied by inflammatory pain. Local inflammatory response does not only play a role in healing but also makes the process painful due to the sustained release of mediators which sustain nociceptor sensitization [11]. The presence of edema and pressure within the tissues also adds to the pain by crushing nerve terminals. The severity and the period of inflammatory pain depends on the severity of tissue damage, the method used in surgery, and the postoperative conditions, which may include infection or dry socket. Neuropathic pain can develop as a result of direct and indirect damage to peripheral nerves, e.g. inferior alveolar nerve or lingual nerve. The nature of this kind of pain is the change of sensations such as burning, tingling or electric shock-like symptoms that may continue to occur after the estimated healing time [12]. The neuropathic processes include abnormal nerve regeneration, ectopic release of impulses, and alterations of ion channels that all lead to the formation of chronic pain syndromes. Figure 1 shows the pathophysiological mechanisms of postoperative pain in oral and maxillofacial surgery.



Figure 1: Pathophysiology of Postoperative Pain in Oral and Maxillofacial Surgery

Oral and maxillofacial surgery greatly depends on psychological and behavioral aspects of modulating pain perception. The factors that are linked with the pain intensity that occurs after the operation are preoperative anxiety, fear and prior poor dental experience. These factors affect the central pain processing and can increase the peripheral and central sensitization mechanisms. Moreover, personal differences in genetic influences, pain toleration and coping mechanisms also leads to the variations in the experience of pain between patients [13].

These mechanisms are useful in understanding how to apply pharmacological interventions. Effective pain management is necessary based on analgesic techniques that prevent the synthesis of inflammatory mediators, inhibit nerve conduction, or alter the central pain circuits in pain management. The incorporation of mechanistic knowledge in clinical practice facilitates the formulation of multimodal analgesic strategies that would ensure the minimization of pain and reduction of adverse effects [14].

Classification of the pharmacological agents

The pharmacological agents that are involved in management of surgical pain during oral and maxillofacial surgeries can be categorized under general groups depending on the mechanism of action and their therapeutic functions. This categorization helps to make rational choice of drugs and helps to administer multimodal analgesia. The initial treatment to most of the postoperative dental pain is through non-opioid analgesics [15]. Acetaminophen (paracetamol) is popular because of its central analgesic effects and desirable safety aspects when it is used within the therapeutic indices. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac and ketorolac are painkillers that work by inhibiting cyclooxygenase (COX) enzymes thus lowering the production of prostaglandins and inflammation. COX-2 selective inhibitors have the same analgesic effect and fewer gastrointestinal adverse effects, but there is still the concern of the cardiovascular risk [16].

Opioid analgesics are used when the moderate and severe pains are not controlled by the non-opioid agents. Weak opioid like codeine and tramadol are usually used in conjunction with non-opioid painkillers to increase their effect. Therefore morphine and oxycodone are strong opioids, which are not as frequently used in dental practice as they are more prone to causing adverse effects and result in dependence [17]. The present tendency is focused on reducing opioid consumption by different means. The action of major analgesic classes of drugs along the pain pathway is represented in Figure 2.



Figure 2: Mechanism of Action of Major Analgesic Drug Classes

Adjuvant analgesics are supportive agents of pain management because they address certain mechanisms. Dexamethasone, corticosteroids, can be used to decrease the intensity of postoperative inflammation, edema and pain. Anticonvulsants, such as gabapentin and pregabalin, are another effective drug of neuropathic pain treatment with the effect of regulating calcium channel activity and decreasing the level of neuronal excitability. Antidepressants can also be used in chronic pain disorders because of their impact on neurotransmitter effects [18].

Intraoperative and immediate postoperative pain management are incomplete without the use of local anesthetics. Sodium channels are blocked by agents like lidocaine, bupivacaine and articaine and cause the prevention of conduction of nerve impulses. Prolonged analgesics such as bupivacaine are associated with prolonged analgesia and decreased systemic drug use during the first postoperative days. Pharmacological agents that are applied in management of oral and maxillofacial pains are categorized as indicated in Table 1.

Table 1: Classification of Pharmacological Agents Used in Oral and Maxillofacial Pain Management

Drug Class	Examples	Mechanism of Action	Clinical Use	Reference
Non-opioid analgesics	Ibuprofen, Diclofenac, Paracetamol	Inhibit COX enzymes, reduce prostaglandins	First-line for mild–moderate pain	[17]
COX-2 inhibitors	Celecoxib, Etoricoxib	Selective COX-2 inhibition	Alternative to NSAIDs	[7]
Opioids	Codeine, Tramadol, Morphine	μ-opioid receptor agonists	Moderate–severe pain	[14]
Corticosteroids	Dexamethasone	Anti-inflammatory, cytokine suppression	Reduces edema and pain	[17]
Local anesthetics	Lidocaine, Bupivacaine, Articaine	Sodium channel blockade	Intraoperative analgesia	[18]
Adjuvants	Gabapentin, Pregabalin	Modulate calcium channels	Neuropathic pain	[19]
Emerging agents	NAV1.8 inhibitors	Selective sodium channel inhibition	Opioid-sparing analgesia	[1]

The pharmacological options are widening the horizon of pain management by new drugs. The sodium channel blockers, including NAV1.8, are novel sodium channel inhibitors, which inhibit peripheral nociceptive pathways with fewer side effects occurring at the central part. The local anesthetics among other agents have their action time prolonged by the use of liposomal drug delivery systems. Also, the studies on selective anti-inflammatory compounds and biologics give promise of more precise and safer analgesic therapy [19].

Such classification reiterates the significance of the choice of the right agents depending on the nature and intensity of pain, characteristics of the patient, and the safety concern. The rationale behind the success of multimodal analgesia in the oral and maxillofacial surgery lies in the integration of multiple classes of drugs with complementary modes of action.

Preoperative Pharmacological Preparations

Preoperative pharmacological management tailored at noreceptive pathways is aimed at mitigating the severity of the postoperative pain, before it can be caused by surgery. This is also known as preemptive analgesia, which is suggested to preclude peripheral and central sensitization by use of analgesic agents before tissue trauma [20]. Preoperative strategies have become an issue that has been receiving interest in oral and maxillofacial surgery, as they may enhance the level of postoperative comfort and limit the necessity of rescue analgesics.

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) as preoperative agents is commonly based on their inhibitory effect on the production of prostaglands during the mediation of cyclooxygenase [21]. NSAIDs should be used to reduce the inflammatory process and the severity of pain in the early postoperative phase. Equally, paracetamol could be applied preoperatively because of its analgesic properties, which differ in the central nervous system, and in association with NSAIDs to increase its effects through complementary effects.

Dexamethasone and other corticosteroids have widespread use in the preoperative room to lower swelling, edema, and trismus. Anti-inflammatory actions help to reduce the postoperative pain and enhance functional recovery. It has been observed that preoperative corticosteroid is especially helpful in surgical intervention of widely-tissue manipulation like surgery of impacted third molar [22]. Another component of preemptive analgesia is local anesthetics used before the incision and is done by either infiltration or nerve block. These agents inhibit intraoperative nociceptive input and consequential central sensitization by preventing nerve conduction of preoperative insult. Prolongation of analgesic effects into the post-surgical phase can be achieved by using long-acting local anesthetics to improve pain management [23].

Gabapentinoids, which are adjunctive agents, have also been studied to use before surgery especially in patients where one expects neuropathic pain. These agents alter neuronal excitability, and could decrease the intensity of postoperative pain but their common application in the dental practice is still under evaluation because of their side effects like sedation and dizziness.

Regardless of the theoretical benefits of preemptive analgesia, the outcomes in clinical practice can be different based on the choice of the drug and timing, dose and patient characteristics. Patient safety should be enhanced by paying close attention to contraindications and other adverse effects. The preoperative pharmacological approaches must, therefore, be incorporated as part of a wider multimodal approach to pain management depending on the needs of patients [24].

Acute Pain Management in the Operating Room

The management of intraoperative pain in oral and maxillofacial surgery aims at reducing the nociceptive input during the process and maximizing the analgesia in the early postoperative period. Proper intraoperative interventions help in lowering the intensity of pain, analgesic needs, and patient outcomes. The intraoperative pain control is based on the local anesthesia. The methods that are normally used to provide adequate analgesia include nerve blocks, infiltration anesthesia and regional anesthesia [25]. The most popular agents are lidocaine, articaine and bupivacaine which have different pharmacokinetic profiles. The choice of anesthetic agent can be limited by the length of the procedure and its

complexity as well as by patient-related factors. Bupivacaine is especially beneficial in the use of long-acting anesthetic in order to deliver longer postoperative pain relief.

Combination of vasoconstrictors like epinephrine with the use of local anesthetics increases efficacy of local anesthetics by increasing the duration of action and decreasing systemic absorption. It is also associated with better hemostasis that is useful during surgical operations that involve high vascular tissues. In many cases, sedation methods, such as conscious sedation by use of agents like midazolam or propofol are used to minimize anxiety in patients and enhance the tolerability of the procedure [26]. Even though sedation does not produce analgesia as such it enhances the general comfort of the patient and may have an indirect effect on pain. General anesthesia might be necessary in more complicated cases, especially the cases involving extensive maxillofacial surgery. Figure 3 demonstrates the idea and clinical practice of multimodal analgesia in oral surgery.



Figure 3: Multimodal Analgesia Model in Oral and Maxillofacial Surgery

Adjunctivical intraoperative pharmacological interventions are the use of opioids or non- opioid analgesics to increase pain management. Hospital systems could use patient-controlled analgesia (PCA) to enable the individualized administration of the analgesics especially after major surgical procedures like oral cancer resections [27]. The latest innovation in the intraoperative pain management is the adoption of perioperative nerve blockade methods and the implementation of multimodal analgesic regimens. The purpose of these methods is to decrease intraoperative nociceptive inputs and enhance the postoperative outcomes by using a combination of agents with diverse mechanisms of action [28].

On the whole, the management of intraoperative pain must be carefully planned and coordinated in order to achieve successful analgesia with the lowest possible negative outcomes. A combination of local anesthesia, sedation and adjunctive pharmacological agents is the foundation of an integrated approach to intraoperative pain management.

Multimodal Analgesia

Multimodal analgesia is a modern method of analgesia treatment that implies the introduction of many pharmacological agents with different mechanisms of action to ensure a high level of analgesia and reduce side effects. This approach is of special interest in the context of oral and maxillofacial surgery as the postoperative pain has a multifactorial nature (including inflammatory, nociceptive and, in some cases, neuropathic components) [29]. The concept of the multimodal analgesia is justified by the principle of addressing along the pathway of pains. Combining peripheral and central acting drugs allows the achievement of additive and synergistic effects, thus pain relief but without any increment in the dose of a specific agent. As an illustration, NSAIDs used together with paracetamol has both peripheral anti-inflammatory and central analgesic effects, making the treatment better than monotherapy [30].

Multimodal regimens may also consist of a combination of non-opioid analgesics, local anesthetics and adjuvant agents used in clinical practice. Most regimens rely on NSAIDs because it is an effective way of curbing inflammation. Analgesic activity is often augmented with paracetamol. Intraoperative or long-acting protocols of local anesthetics add to the long-term pain relief during the first hours of the after-surgery. Corticosteroids can also be added in some cases to decrease the inflammation and edema, which will help the patient even more.

The administration of opioids as part of multimodal analgesia is progressively restricted to situations of intense pain which cannot be effectively managed by non-opioid. Opioids should be used at low dosages when used as part of combination therapy and this limits the risk of adverse effects of the drug which are respiratory depression, nausea and dependence. This is a primary benefit of multimodal analgesia and it is beneficial to the existing efforts to practice-based approaches in reducing opioid prescribing in dental practice [31]. Table 2 presents the common multimodal analgesic combinations together with their clinical benefits.

Table 2: Multimodal Analgesic Combinations and Their Clinical Benefits

Combination	Mechanism Synergy	Clinical Benefit	Opioid-Sparing Effect	Reference
Ibuprofen + Paracetamol	Peripheral + central action	Superior analgesia	High	[17]
Ibuprofen + Caffeine	Enhanced analgesic potentiation	Improved pain relief	Moderate	[13]
NSAID + Corticosteroid	Anti-inflammatory synergy	Reduced swelling and pain	Moderate	[31]
Local anesthetic + NSAID	Nerve block + inflammation control	Prolonged analgesia	Moderate	[28]
NSAID + Opioid	Peripheral + central opioid action	Severe pain management	Low–moderate	[8]

New evidence suggests the application of other adjuvant agents like gabapentinoids, under certain cases of clinical application. These agents could be effective in preventing neuropathic aspects of pain or in those procedures which could be accompanied by intense postoperative pain. Their use is however not common because of the side effects that they may cause and also because of the inconsistency in clinical results. The use of multimodal analgesia must be done with a close consideration of drug interactions, patient-specific aspects and characteristics of the procedure. Treatment plans that are individualized are necessary to ensure maximum efficacy and safety. Altogether, multimodal analgesia is an efficient and evidence-based approach to the enhancement of pain management and clinical outcomes in oral and maxillofacial surgery.

Safety and Adverse Effects

One of the most important factors in the oral and maxillofacial surgery is the safety profile of the pharmacological agents to be employed in the management of pains. Although analgesia is crucial, possible side effects also require the careful choice and control of drugs [32] . NSAIDs are well-used given their effectiveness in controlling inflammatory pain, but also known to cause gastrointestinal irritation, ulceration and bleeding especially when they are used over a long period of time or when they are administered to patients with underlying gastrointestinal problems. NSAIDs can also affect the renal functioning and risk of cardiovascular dysfunction, particularly when it is in elderly patients or comorbidities. Also, their antiplatelet effect can cause increased bleeding during and after surgery [33].

Despite their use in the treatment of severe pain, opioid analgesics are associated with serious side effects such as respiratory depression, sedation, nausea and vomiting, constipation, and tolerance and dependence. The presence of the threat of opioid misuse has contributed to the greater scrutiny of the practice of prescribing opioids, focusing on the prescription of opioids in limited terms and based on certain conditions. These risks can be countered by patient education and monitoring [35].

The adverse effects of corticosteroids which are widely used due to their anti-inflammatory effects include; immunosuppression, retarded wound healing, hyperglycemia, and gastrointestinal disturbances. These are usually dose-dependent and more so when used over a long period of time, but usually well tolerated in short-term perioperative administration. Mostly the use of local anesthetics is safe when used in the standard dose, but, systemic toxicity may occur when large doses are used or inadvertent intravascular injection occurs. The symptoms of the local anesthetic systemic toxicity manifestation include such central nervous system symptoms as dizziness, seizures, and cardiovascular collapse in the severe cases. The right technique and dosing schedules should be used to reduce such risks [35].

Adjuvant analgesics can have the side effects of sedation, dizziness, and impaired cognition (gabapentinoids and antidepressants). These effects could be especially important in the geriatric patients or when in combination with other central nervous system depressants. Table 3 presents the safety profile and side effects of the most common analgesics.

Table 3: Safety Profile and Adverse Effects of Common Analgesics

Drug Class	Common Adverse Effects	Serious Risks	Contraindications	Reference
NSAIDs	Gastric irritation, nausea	GI bleeding, renal impairment	Peptic ulcer, renal disease	[27]
Opioids	Sedation, constipation	Respiratory depression, dependence	Substance abuse risk	[24]
Corticosteroids	Hyperglycemia	Immunosuppression, delayed healing	Diabetes, infection	[27]
Local anesthetics	Numbness, dizziness	CNS/cardiac toxicity	Overdose risk	[38]
Gabapentinoids	Drowsiness, dizziness	CNS depression	Elderly caution	[29]

Interactions between drugs are also another safety concern. The use of several drugs at the same time can enhance the development of adverse effects or change drug metabolism. Indicatively, NSAIDs and anticoagulants might interact to promote bleeding whereas opioids and sedatives might interact to promote respiratory depression. Age and comorbidities, as well as genetic variability, are patient-specific factors, which affect drugs and predisposition to adverse effects. Personalized treatment planning and close monitoring are also therefore important elements of safe pharmacological pain management.

Pharmacological Management of the Postoperative Period

Pharmacological pain management in the postoperative room is an essential part of pain management of oral and maxillofacial surgery, where most of the pain is observed when anesthesia is already over. Postoperative analgesia is necessary so that it enhances recovery, patient satisfaction, and avert some complications related to insufficient analgesia [36]. A gradual method is widely used in managing postoperative pain starting with the use of non-opioid analgesics as the initial treatment. NSAIDs are also considered the most effective in the management of inflammatory pain in patients after dental procedures. Their effects of minimizing the inflammatory effects of prostaglandins, render them especially advantageous to ailments like extracting the third molar. NSAIDs are frequently combined with Paracetamol to give additive effects [37].

In patients with moderate to severe pains, opioids can be used as a supplement to non-opioids. They are, however, gradually becoming a limited use because of the conceived adverse effects and misuse of them. There are instances where short courses of low dose opioids can be taken under close supervision and education of the patient [39].

The multimodal analgesia is one of the fundamental principles of managing pain after surgery. Possibly, combining agents with varied mechanisms of action will result in better pain management and may lead to a decrease in the doses of individual drugs. Indicatively, a mixture of ibuprofen and paracetamol has been found to give better analgesia than either of the two agents. Adjunctive techniques, including corticosteroids and local anesthetics can be used to promote analgesia. Table 4 describes the pharmacological interventions during the preoperative, intraoperative and postoperative periods.

Table 4: Pharmacological Strategies Across Surgical Phases

Surgical Phase	Pharmacological Strategy	Drugs Used	Clinical Outcome	Reference
Preoperative	Preemptive analgesia	NSAIDs, Paracetamol	Reduced postoperative pain	[12]
Preoperative	Anti-inflammatory prophylaxis	Dexamethasone	Reduced edema, trismus	[41]
Intraoperative	Local anesthesia	Lidocaine, Bupivacaine	Pain-free surgery	[38]
Intraoperative	Sedation/adjuncts	Fentanyl, Midazolam	Improved patient comfort	[8]
Postoperative	First-line analgesia	NSAIDs, Paracetamol	Effective pain control	[2]
Postoperative	Rescue analgesia	Opioids	Severe pain control	[24]
Postoperative	Multimodal therapy	Combination regimens	Improved recovery	[17]

In patients who have failed to manage pain adequately with the initial treatment, rescue analgesia is an issue to be considered. This can be through increased dosage of the drug, introduction of opioid-acting agents, or the adoption of other pharmacological substances. In hospitals, patient-controlled analgesia can be used to enable patients to control their pain individually. The period of analgesic therapy after the surgical operation needs to be customized to the anticipated pain status and the type of procedure [40]. Majority of dental

interventions involve a brief analgesia whose duration is usually few days to one week. The use of analgesics should be minimized by avoiding their prolonged use to limit the occurrence of adverse effects. Individual patient characteristics such as age, medical history, and concomitant medication should be factored to determine postoperative analgesic regimens. To ensure that the best results are obtained, clear communication and education of patients about dosing, possible side effects, as well as adherence are involved.

Special Populations Of Patients

The specificity of pharmacological management of pain in special patients groups is necessitated by physiological differences, comorbid factors, and higher risks of adverse effects. There are specific needs of pediatric, geriatric, medically compromised, and pregnant patients in oral and maxillofacial surgery [42]. Children are a special problem because of variation in the metabolism of drugs, developmental physiology, and pain communication. To guarantee safety and efficacy, it is necessary to use weight-based dosing. The first-line agents are usually NSAIDs and paracetamol, and the opioids are used in severe pain indicators and need close monitoring because of the possibility of respiratory depression. This population may also have some considerable impact on pain perception due to the presence of behavioral factors and anxiety [43].

Geriatric patients are usually comorbid and can be under various medications which increases chances of drug interactions and adverse effects. The metabolism and clearance of drugs can change with age due to the alteration of normal age-related renal and hepatic functions. The use of NSAIDs may be cautious because of potential effects on the kidneys and heart, whereas Opioids should have their doses altered to reduce the sedation effect and respiratory depression. It is usually desired to use multimodal analgesia with lower doses.

Individual analgesic regimens are needed in medically compromised patients, such as heart disease, diabetes, kidney impaired, or liver dysfunction. NSAIDs can be contraindicated in patients with renal or cardiovascular disease whereas corticosteroids can worsen glycemic regulation in diabetic patients. To prevent complications, it is necessary to choose analgesics carefully and monitor them strictly [44].

Another special population where the drug safety is of the utmost importance is that of pregnant and lactating women. Most analgesics bypass the placental barrier or are exuded in breast milk, and they may have an effect on the unborn or the infant. The use of paracetamol is generally safe when taken in the right amount and NSAIDs are generally avoided during the third trimester because of the fetal complications that may occur. Opioids can be administered in short-term intervals when it is required. The psychological factors such as anxiety and fear are especially applicable in such populations and can contribute to understanding and treatment of the pain. To attain the best pain management, a multi-modal method combining both pharmacological and non-pharmacological treatment may be needed.

Clinical Evidence and Outcomes

Functional recovery is a significant outcome that is assessed to indicate the capacity of patients to resume normal functions, such as food intake, oral speech, and oral hygiene. Proper management of pain enhances early mobilization and prevents the effects of postoperative pain on normal functioning. Poor analgesia, conversely, can result in a slow healing process and reduced life quality. Patient satisfaction is highly associated with pain management and general experience in treatment. When patients experience good and well-tolerated analgesic schedules, they will be more likely to record positive results and compliance with the instructions given to them after the operation [45]. The role of communication and education on pain management is important to influence patient expectations and satisfaction. Other outcomes relate to effective pain management and involve reduction in complications. Sufficient analgesia can reduce the chances of developing postoperative complications like infection, slow healing and development of chronic pain. On the other hand, uncontrolled pain may also add to the escalation of stress reactions and healing problems. The algorithm of clinical decision-making in pharmacological pain management is provided in Figure 4.



Figure 4: Clinical Decision-Making Algorithm for Surgical Pain Management

The comparative effectiveness studies are an important source of information on the relative advantages and risks of various pharmacological strategies. There is evidence that suggests multimodal analgesia is a better method that can be used to deliver the best results with minimal side effects. Nonetheless, inconsistency in the study design, patient groups, and outcome measurements poses a problem in consolidating evidence and coming up with uniform guidelines. Gestalt, the clinical outcomes provide evidence on the significance of evidence-based and patient-centered interventions in oral and maxillofacial surgery regarding drug use in the management of pain.

Future Directions

The development of pharmacological pain management is becoming more and more aimed at enhancing the effectiveness and minimizing side effects and variations of treatment effect. The related trends in oral and maxillofacial surgery are new developments in drug development, personalized medicine, and integration of technology. Among the most significant ones, one should note the availability of new non-opioid analgesics that focus on the specific molecular processes of transmitting pain. The NAV1.8 blocker is a promising category of drugs, which offers effective analgesia with no central nervous system impact of opioids. These agents can revolutionize the use of acute pain management with safer options of moderate to severe pain. Another area of increasing interest is pharmacogenomics, which can be used to provide personalized analgesic therapy as a result of genetic profiles. Individual responses to analgesics may be affected by differences in genes affecting the metabolism of drugs, sensitivity of receptors and inflammatory reactions. With the integration of pharmacogenomic data in clinical practice, there is likely to be an improvement in drug selection, optimization of drug dosage, and the risk of drug adverse effects. An improvement in the pain management is also being brought by innovations in drug delivery systems. Local anesthetics and other analgesics may have their durations of action increased by using liposomal formulations and sustained-release preparations that decrease the frequency of administration. These technologies increase the ease of patients and can increase the adherence to treatment.

Conclusion

The pharmacological treatment of oral and maxillofacial postoperative pain is a very important aspect of patient treatment and has direct implications on recovery, functional and overall treatment experience. The progress in study in the field of the mechanisms of pain and construction of different painkillers have allowed to control pain more effectively and precisely. The use of non-opioid analgesics especially NSAIDs and paracetamol is the cornerstone of pain management plan with the use of opioids increasingly becoming the reserve option in some select circumstances because of their risks. Multimodal analgesia has been adopted and it is a potent intervention which has had a significant impact on clinical outcomes as agents with complementary mechanisms are used to maximize efficacy and minimize adverse effects. The safety still remains the primary point of analgesic choice and it is necessary to pay especial attention on reducing the complications and taking into consideration factors specific to particular patient. Special populations such as pediatric, geriatric and medically compromised patients need to have tailored approaches. New approaches with the potential to improve pain management include new therapeutics such as non-opioid agents, novel drug delivery approaches and the concept of personal medicine. Nevertheless, the problems related to various issues such as differences of clinical practice and inadequacy of current evidence base for the performance of guidelines emphasizes the need for further research and optimization of guidelines. Pharmacological and maxillofacial surgery requires a complex, evidence-based and patient-oriented method to maximise analgesia and prevent harm at the same time as the overall clinical outcomes are enhanced through success in the analgesia treatment process.

REFERENCES

1. McCoun J, Winkle P, Solanki D, Urban J, Bertoch T, Oswald J, et al. Suzetrigine, a non-opioid NAV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain. J Pain Res. 2025;18:1569–76. DOI: 10.2147/JPR.S40165940
2. Feldman CA, Fredericks-Younger J, Desjardins PJ, Malmstrom H, Miloro M, Warburton G, et al. Nonopioid vs opioid analgesics after impacted third-molar extractions. J Am Dent Assoc. 2025;156(2):110–123.e9. DOI: 10.1016/j.adaj.2024.11.005
3. Hamoda MM, Huynh N, Ayas NT, Rompré P, Bansback N, Masse JF, et al. Continuous positive airway pressure and mandibular advancement splints: the CHOICE multicentre, open-label randomised clinical trial. Eur Respir J. 2025;65(4):2401100. DOI: 10.1183/13993003.01100-2024
4. Agbulut N. Assessing nerve injuries in oral surgery: a survey-based study on prevention and management. Med Oral Patol Oral Cir Bucal. 2025;30(3):e462–8. DOI: 10.4317/medoral.26218
5. Mitchell SG, Truitt AR, Davin LM, Rindal DB. Pain management after third molar extractions in adolescents: a qualitative study. BMC Pediatr. 2022;22(1):184. DOI: 10.1186/s12887-022-03255-0
6. Alshehri TA, Alameer ST, Almotreb AM. Strategical ways for dental anxiety management prior to third molar extraction. Cureus. 2024;16(8):e68023. DOI: 10.7759/cureus.68023
7. Jose A, Rawat A, Singh S, Nagori SA, Roychoudhury A. Management of intraoral surgical defects using sublingual gland flap. J Craniofac Surg. 2020;31(8):e766–7. DOI: 10.1097/SCS.0000000000006766
8. Park KN, Ryoo SH, Karm MH, Kim HJ, Seo KS. Analysis of the effect of fentanyl dosage used in patient-controlled analgesia for pain management after oral cancer surgery: a retrospective observational study. J Dent Anesth Pain Med. 2025;25(1):43. DOI: 10.17245/jdapm.2025.25.1.43
9. Sourvanos D, Lander B, Sarmiento H, Carroll J, Hall RD, Zhu TC, et al. Photobiomodulation in dental extraction therapy. J Am Dent Assoc.

2023;154(7):567–79. DOI: 10.1016/j.adaj.2023.03.015
10. Chronic post-surgical pain following the placement of dental implants in the maxilla: a case series. 2016. DOI: 10.1016/j.joms.2016.03.020
11. Babu SJ, Jayakumar NK, Siroraj P. Efficacy of intraosseous saline injection for pain management during surgical removal of impacted mandibular third molars: a randomized double-blinded clinical trial. J Dent Anesth Pain Med. 2023;23(3):163. DOI: 10.17245/jdapm.2023.23.3.163
12. Cooper SA, Desjardins P, Brain P, Paredes-Diaz A, Troullos E, Centofanti R, et al. Longer analgesic effect with naproxen sodium than ibuprofen in post-surgical dental pain: a randomized, double-blind, placebo-controlled, single-dose trial. Curr Med Res Opin. 2019;35(12):2149–58. DOI: 10.1080/03007995.2019.1654385
13. Weiser T, Richter E, Hegewisch A, Muse DD, Lange R. Efficacy and safety of a fixed-dose combination of ibuprofen and caffeine in the management of moderate to severe dental pain after third molar extraction. Eur J Pain. 2018;22(1):28–38. DOI: 10.1002/ejp.1091
14. Lanzetti J, Crupi A, Ronsivalle V, Minervini G, Russo D, Bramanti E, et al. Non-surgical management of gingival cleft. Minerva Dent Oral Sci. 2025;74(2):138–45. DOI: 10.23736/S2724-6329.24.04615-5
15. Bae SH, Shim GJ, Kwon TG. Diagnosis and management of persistent idiopathic facial pain following dental procedures: a retrospective study. J Korean Assoc Oral Maxillofac Surg. 2025;51(5):269–77. DOI: 10.5125/jkaoms.2025.51.5.269
16. Thorat SD, Nilesh K. Efficacy of low-level laser therapy in the management of postoperative surgical sequelae after surgical removal of impacted mandibular third molars. Natl J Maxillofac Surg. 2022;13(Suppl 1):S52–6. DOI: 10.4103/njms.njms_143_21
17. Moore PA, Hersh EV. Combining ibuprofen and acetaminophen for acute pain management after third-molar extractions. J Am Dent Assoc. 2013;144(8):898–908. DOI: 10.14219/jada.archive.2013.0207
18. Predictive and relative factors of dental anxiety among third molar disimpaction patients in a Northern Nigerian hospital. 2023. DOI: 10.4103/ajm.AJM_56_22
19. Sancak KT, Akal ÜK. Effect of verbal and written information and previous surgical experience on anxiety during third molar extraction. J Oral Maxillofac Surg. 2019;77(9):1769.e1–1769.e7. DOI: 10.1016/j.joms.2019.05.013
20. Wong NSM, Yeung AWK, Li KY, McGrath CP, Leung YY. Non-pharmacological interventions for reducing fear and anxiety in patients undergoing third molar extraction under local anesthesia: systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(18):11162. DOI: 10.3390/ijerph191811162
21. Plachy R, Krejčová L, Machon V, Bujda M. Impact of paper information leaflets on dental anxiety and well-being in Czech patients: a randomized clinical trial. J Int Soc Prev Community Dent. 2025;15(1):69–79. DOI: 10.4103/jispcd.JISPCD_321_24
22. Lin CS, Wu SY, Yi CA. Association between anxiety and pain in dental treatment: a systematic review and meta-analysis. J Dent Res. 2017;96(2):153–62. DOI: 10.1177/0022034516676887
23. Chapman P. Chest pain in the dental surgery: a brief review and practical points in diagnosis and management. Aust Dent J. 2002;47(3):259–61. DOI: 10.1111/j.1834-7819.2002.tb00336.x
24. Fiore JF, El-Kefraoui C, Chay MA, Nguyen-Powanda P, Do U, Olleik G, et al. Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials. Lancet. 2022;399(10343):2280–93. DOI: 10.1016/S0140-6736(22)00540-9
25. Potter C, Ritson Z, Walton G, Coats L, Irvine T, Ohlsen-Turner K. The heart of it: dental care and cardiothoracic surgery. Br Dent J. 2024;237(1):33–9. DOI: 10.1038/s41415-024-7123-5
26. Pain-related complaints of paediatric patients after dental treatment under general anaesthesia. Eur J Paediatr Dent. 2023;24(1). DOI: 10.23804/ejpd.2023.24.01.11
27. Pergolizzi JV, Magnusson P, LeQuang JA, Gharibo C, Varrassi G. The pharmacological management of dental pain. Expert Opin Pharmacother. 2020;21(5):591–601. DOI: 10.1080/14656566.2020.1721468
28. Lopez-Lopez J, Ramezanzade S, Atabaki M, Sadeghi E. Psychologic status and influence of surgery techniques on acute nonneuropathic pain after dental implant surgery: systematic review and meta-analyses. Int J Oral Maxillofac Implants. 2021;36(2):248–69. DOI: 10.11607/jomi.8283
29. Alantar A, Béatrix JC, Marti G, Princ G, Rei N, Missika P, et al. Neuropathic pain after dental implant surgery: literature review and proposed algorithm for medicosurgical treatment. J Oral Implantol. 2023;49(2):218–27. DOI: 10.1563/aaid-joi-D-22-00161
30. Lobprise H, St Denis K, Anderson JG, Hoyer N, Fiani N, Yaroslav J. 2025 felineVMA feline oral health and dental care guidelines. J Feline Med Surg. 2025;27(11):1098612X251398793. DOI: 10.1177/1098612X251398793
31. Allende JB, Caviedes R, Von Marttens A, Ramírez FG, Piña IV, Kuga M, et al. Effectiveness of low-level laser therapy in reducing postoperative pain after dental implant surgery: a randomized clinical trial. Photodiagnosis Photodyn Ther. 2024;49:104293. DOI: 10.1016/j.pdpdt.2024.104293
32. Onwuka C, Udeabor S, Al-Hunaif A, Al-Shehri WK, Al-Sahman L. Does preoperative dental anxiety play a role in postoperative pain perception after third molar surgery? Ann Afr Med. 2020;19(4):269. DOI: 10.4103/aam.aam_40_19
33. Kaboosaya B, Win KZ, Arunjaroensuk S, Pimkhaokham A. Evaluating pain relief after dental implant surgery using 0.3% benzydamine hydrochloride spray: a double-blind, randomized clinical trial. J Oral Implantol. 2025;52(1):46–52. DOI: 10.1563/aaid-joi-D-23-00123

34. Akomolafe AG, Fatusi OA, Folayan MO, Mosaku KS, Adejobi AF, Njokanma AR. Relationship between types of information, dental anxiety, and postoperative pain following third molar surgery: a randomized study. J Oral Maxillofac Surg. 2022;81(3):329–36. DOI: 10.1016/j.joms.2022.09.008
35. Samieirad S, Mianbandi V, Shiezadeh F, Hosseini-Abrishami M, Tohidi E. Tapered versus cylindrical implant: which shape inflicts less pain after dental implant surgery? J Oral Maxillofac Surg. 2019;77(7):1381–8. DOI: 10.1016/j.joms.2019.02.021
36. Vázquez-Delgado E, Viaplana-Gutiérrez M, Figueiredo R, Renton T, Gay-Escoda C, Valmaseda-Castellón E. Prevalence of neuropathic pain and sensory alterations after dental implant placement in a university-based oral surgery department: a retrospective cohort study. Gerodontology. 2018;35(2):117–22. DOI: 10.1111/ger.12329
37. El-Angbawi A, McIntyre G, Fleming PS, Bearn D. Non-surgical adjunctive interventions for accelerating tooth movement in patients undergoing orthodontic treatment. Cochrane Database Syst Rev. 2023;2023(6):CD010887. DOI: 10.1002/14651858.CD010887.pub3
38. Oono Y, Takagi S, Arendt-Nielsen L, Kohase H. Perioperative nerve blockade reduces acute postoperative pain after orthognathic surgery. Pain Res Manag. 2023;2023:1–9. DOI: 10.1155/2023/38149075
39. Non-pain-related complaints of paediatric patients after dental treatment under general anaesthesia. Eur J Paediatr Dent. 2023. DOI: 10.23804/ejpd.2023.1951
40. Politis C, Agbaje J, Van Hevele J, Nicolielo L, De Laat A, Lambrichts I, et al. Report of neuropathic pain after dental implant placement: a case series. Int J Oral Maxillofac Implants. 2017;32(2):439–44. DOI: 10.11607/jomi.5233
41. Soltaninia O, Shojaee M. Mannitol reduces pain and trismus after impacted mandibular third molar surgery. J Oral Maxillofac Surg. 2024;82(5):572–80. DOI: 10.1016/j.joms.2024.02.006
42. Akl N, Sommerfield A, Slevin L, Drake-Brockman TF, Wong S, Winters JC, et al. Anaesthesia, pain and recovery profiles in children following dental extractions. Anaesth Intensive Care. 2020;48(4):306–13. DOI: 10.1177/0310057X20942672
43. Lee KC, Bassiur JP. Salivary alpha amylase, dental anxiety, and extraction pain: a pilot study. Anesth Prog. 2017;64(1):22–8. DOI: 10.2344/anpr-64-01-22
44. Christensen SE, Cooper SA, Mack RJ, McCallum SW, Du W, Freyer A. A randomized double-blind controlled trial of intravenous meloxicam in the treatment of pain following dental impaction surgery. J Clin Pharmacol. 2018;58(5):593–605. DOI: 10.1002/jcph.1058
45. Sivakumar S, Venkiteswaran A, Roslan MA, Musa S. Assessing modalities used to alleviate postoperative pain in children receiving dental treatment under general anaesthesia: a systematic review. J Clin Pediatr Dent. 2024;48(3):15. DOI: 10.22514/jocpd.2024.015